Atea Pharmaceuticals (AVIR) Cash from Operations (2019 - 2026)

Atea Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 46391000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 51.79% year-over-year to 46391000.0; the TTM figure through Mar 2026 stood at 147859000.0 (down 17.17% YoY), while the FY2025 annual figure was 132031000.0, up 2.56% from the prior year.
• Cash from Operations was 46391000.0 for Q1 2026 at Atea Pharmaceuticals, down from 28223000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 16120000.0 in Q2 2023 to a low of 59009000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 30605764.71 across 5 years, with a median of 29850000.0 in 2023.
• Biggest YoY gain for Cash from Operations was 71.43% in 2022; the steepest drop was 250.47% in 2022.
• A 5-year view of Cash from Operations shows it stood at 21545000.0 in 2022, then fell by 1.34% to 21834000.0 in 2023, then slumped by 39.22% to 30397000.0 in 2024, then advanced by 7.15% to 28223000.0 in 2025, then tumbled by 64.37% to 46391000.0 in 2026.
• The last three Cash from Operations figures came in at 46391000.0 (Q1 2026), 28223000.0 (Q4 2025), and 40375000.0 (Q3 2025), per Business Quant data.